经鼻高流量湿化氧疗对小儿扁桃体腺样体手术麻醉复苏期呼吸系统不良事件的影响

注册号:

Registration number:

ChiCTR2100054638 

最近更新日期:

Date of Last Refreshed on:

2022-11-27 14:31:15 

注册时间:

Date of Registration:

2021-12-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经鼻高流量湿化氧疗对小儿扁桃体腺样体手术麻醉复苏期呼吸系统不良事件的影响

Public title:

Effect of high-flow nasal cannula oxygen therapy on respiratory adverse events during anesthesia recovery period of pediatric adenotonsillectomy and adenoidectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经鼻高流量湿化氧疗对小儿扁桃体腺样体手术麻醉复苏期呼吸系统不良事件的影响

Scientific title:

Effect of high-flow nasal cannula oxygen therapy on respiratory adverse events during anesthesia recovery period of pediatric adenotonsillectomy and adenoidectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

魏玮 

研究负责人:

李文献 

Applicant:

Wei Wei 

Study leader:

Li Wenxian 

申请注册联系人电话:

Applicant telephone:

+86 18101805988

研究负责人电话:

Study leader's
telephone:

+86 13917426838

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

weiwei@eentanesthesia.com

研究负责人电子邮件:

Study leader's E-mail:

liwenxian@eentanesthesia.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区汾阳路83号

研究负责人通讯地址:

上海市徐汇区汾阳路83号

Applicant address:

83 Fenyang Road, Xuhui District, Shanghai, China

Study leader's address:

83 Fenyang Road, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属眼耳鼻喉科医院

Applicant's institution:

Eye & ENT Hospital, Fudan University

研究负责人所在单位:

复旦大学附属眼耳鼻喉科医院

Affiliation of the Leader:

Eye & ENT Hospital, Fudan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2021]伦审字第(2021152)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属眼耳鼻喉科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Eye & ENT Hospital, Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-11-24 00:00:00

伦理委员会联系人:

周行涛

Contact Name of the ethic committee:

Zhou Xingtao

伦理委员会联系地址:

上海市徐汇区汾阳路83号

Contact Address of the ethic committee:

83 Fenyang Road, Xuhui District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属眼耳鼻喉科医院

Primary sponsor:

Eye & ENT Hospital, Fudan University

研究实施负责(组长)单位地址:

上海市徐汇区汾阳路83号

Primary sponsor's address:

83 Fenyang Road, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属眼耳鼻喉科医院

具体地址:

徐汇区汾阳路83号

Institution
hospital:

Eye & ENT Hospital, Fudan University

Address:

83 Fenyang Road, Xuhui District

经费或物资来源:

课题经费

Source(s) of funding:

Project funding

研究疾病:

麻醉复苏期呼吸系统不良事件  

Target disease:

Respiratory adverse events during anesthesia recovery period

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

主要目的:研究经鼻高流量湿化氧疗(high-flow nasal cannula oxygen therapy,HFNC)在小儿扁腺手术后麻醉复苏期呼吸系统不良事件的影响。  

Objectives of Study:

Main purpose: To study the effect of high-flow nasal cannula oxygen therapy (HFNC) on respiratory adverse events during the anesthesia recovery period of pediatric adenotonsillectomy and adenoidectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.鼻阻塞;
2.先天性心脏病或肺疾病;
3.贫血;
4.上呼吸道感染急性期;
5.患儿或监护人拒绝参加研究。

Exclusion criteria:

1. Nasal obstruction;
2. Congenital heart disease or lung disease;
3. Anemia;
4. The acute phase of upper respiratory tract infection;
5. The patient or guardian refuses to participate in the study.

研究实施时间:

Study execute time:

From 2021-12-01 00:00:00 To 2022-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-22 00:00:00 To 2022-01-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental group

Sample size:

干预措施:

经鼻高流量湿化氧疗

干预措施代码:

Intervention:

Nasal High Flow Humidified Oxygenation Therapy

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

常规拔管

干预措施代码:

Intervention:

Routine extubation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属眼耳鼻喉科医院 

单位级别:

三级甲等 

Institution
hospital:

Eye & ENT Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

呼吸系统不良事件发生率

指标类型:

主要指标

Outcome:

The incidence of respiratory adverse events

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低氧血症发生率及严重程度

指标类型:

次要指标

Outcome:

Incidence and severity of hypoxemia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

应对措施的耗费与效果

指标类型:

次要指标

Outcome:

Cost and effect of response measures

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉护士自评劳动强度

指标类型:

次要指标

Outcome:

Self-assessment of labor intensity by anesthesia nurses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

非呼吸系统不良事件发生率

指标类型:

副作用指标

Outcome:

Non-respiratory adverse events rate

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 7 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用基于随机数字队列的完全随机化,将患者按1:1的比例随机分配到HFNC组和标准组。随机数字队列由SPSS23.0统计软件产生,随机种子号为214231。

Randomization Procedure (please state who generates the random number sequence and by what method):

In this study, complete randomization based on a random number cohort was used. Patients were randomly assigned to the HFNC group and the standard group at a ratio of 1:1. The random number queue is generated by SPSS23.0 statistical software, and the random seed number is 214231.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

受试者设盲

Blinding:

Subjects are blinded

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过邮箱联系研究负责人,且采用临床试验公共管理平台ResMan向公众开放查询, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact by E-mail of study leader, and the data will be published in the public management platform of clinical trials ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用CRF记录病史、治疗过程以及监测结果 使用EXCEL对数据进行电子化管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Using Case Record Form to record History, treatment process and monitoring results. Using Excel to elctronically manage the data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-12-22 09:20:04